Table 1.
Patient characteristics n (%)
| Patient characteristics | Value |
| Number of patients | 38 |
| Patients with ulcerative colitis (UC)/Crohn’s colitis (CC) | 29 (76)/9 (24) |
| Men | 23 (58) |
| Age (yr): mean ± SD | 55.24 ± 14.11 |
| Disease duration (yr): mean ± SD | 17.82 ± 8.29 |
| Number of colonoscopies | 62 |
| Number of colonoscopies in UC/CC | 49 (79)/13 (21) |
| Disease extension1 | |
| Left colitis (UC) or segmentary colitis (CC) | 20 (33) |
| Extensive colitis (UC and CC) | 42 (68) |
| Medication at endoscopy1 | |
| Oral 5-ASA | 40 (65) |
| IMM (AZA/6MP) | 18 (29)/3 (5) |
| TNF inhibitor (IFX/ADA) | 2 (3)/2 (3) |
| CRP (mg/dL): mean ± SD | 8.25 ± 16.56 |
| Fecal calprotectin (μg/g): mean ± SD | 306.5 ± 690.1 |
| Reason for colonoscopy | |
| Endoscopic activity assessment | 5 (8) |
| Dysplasia surveillance | 57 (92) |
| Clinical activity | |
| Active disease | 5 (8) |
| Symptomatic remission | 57 (92) |
| Endoscopic activity | |
| Endoscopic remission | 24 (39) |
| Endoscopic activity | 38 (61) |
| Histological activity and presence of dysplasia | |
| Dysplasia | 8 (13) |
| Acute histological activity | 23 (37) |
| Chronic histological activity | 24 (39) |
| No histological activity | 7 (11) |
| Methylation status | |
| SLIT2 (patients with any methylated sample) | 40 (65) |
| TGFB2 (patients with any methylated sample) | 23 (42) |
1
As therapy regimens overlapped, the total is 104.7%. ASA: Aminosalicylic acid; CS: Corticosteroids; IMM: Immunomodulators; AZA: Azathioprine; 6MP: 6 mercaptopurine; MTX: Methotrexate; TNF: Tumor necrosis factor; IFX: Infliximab; ADA: Adalimumab.